Literature DB >> 30864627

Serum irisin and apelin levels and markers of atherosclerosis in patients with subclinical hypothyroidism.

Hamiyet Yilmaz Yasar1, Mustafa Demirpence1, Ayfer Colak2, Leman Yurdakul3, Merve Zeytinli2, Hakan Turkon4, Ferhat Ekinci5, Aybike Günaslan2, Erdem Yasar6.   

Abstract

OBJECTIVE: In this study, we aimed to evaluate serum irisin and apelin levels in patients with subclinical hypothyroidism (SCH) when they were subclinical hypothyroid and become euthyroid after levothyroxine therapy and association of these adipokines with markers of atherosclerosis such as serum homocysteine levels and carotid intima-media thickness (IMT). SUBJECTS AND METHODS: The study included 160 patients with newly diagnosed subclinical hypothyroidism due to Hashimoto's thyroiditis and 86 euthyroid healty subjects. Serum glucose and lipid profile, insulin, HOMA, TSH, free T3, free T4, anti-thyroperoxidase and anti-thyroglobulin antibodies, homocysteine, apelin and irisin levels were measured in all study subjects. Thyroid and carotid ultrasound examinations were performed. The subclinical hypothyroid group was reevaluated after 12-weeks of levothyroxine therapy when they became euthyroid.
RESULTS: Clinical characteristics of the patient and control group were similar. Glucose, insulin and HOMA levels, lipid parameters and free T3 were similar between the two groups.. Serum homocystein was higher and apelin was lower in patients with SCH, but irisin levels were similar between the two groups. While thyroid volume was lower, carotid IMT was significantly greater in patients with SCH (pCarotidIMT:0,01). After 12-weeks of levothyroxine therapy, all the studied parameters remained unchanged except, serum freeT4, TSH, homocystein and apelin. While homocystein decreased (p: 0,001), apelin increased significantly (p = 0,049). In multivariate analysis, low apelin levels significantly contributed to carotid IMT (p = 0,041).
CONCLUSIONS: Apelin-APJ system may play a role in vascular and cardiac dysfunction in patients with SCH and treatment of this condition may improve the risk of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30864627     DOI: 10.20945/2359-3997000000106

Source DB:  PubMed          Journal:  Arch Endocrinol Metab        ISSN: 2359-3997            Impact factor:   2.309


  6 in total

1.  Correlation of serum apelin level with carotid intima-media thickness and insulin resistance in a sample of Egyptian patients with type 2 diabetes mellitus.

Authors:  Mervat El Shahat El Wakeel; Inass Hassan Ahmad; Marwa Abdelmonim Mohammed; Sally Mohamed Osama Ali; Marwa Khairy Abd El Wahab; Walaa Mohamed Shipl
Journal:  J Res Med Sci       Date:  2022-02-18       Impact factor: 1.852

2.  Secondary hormonal alterations in short-term severe hypothyroidism; in the focus: Apelin and copeptin.

Authors:  Marin Gergics; Gréta Pham-Dobor; Zoltán Horváth-Szalai; Tamás Kőszegi; Emese Mezősi; László Bajnok
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-14       Impact factor: 6.055

3.  Thyroid hormones modulate irisin concentrations in patients with recently onset hypothyroidism following total thyroidectomy.

Authors:  R Bocale; A Barini; A D'Amore; M Boscherin; S Necozione; A Barini; G Desideri; C P Lombardi
Journal:  J Endocrinol Invest       Date:  2020-10-14       Impact factor: 4.256

Review 4.  The role of thyroid hormone in metabolism and metabolic syndrome.

Authors:  Patrícia de Fátima Dos Santos Teixeira; Patrícia Borges Dos Santos; Carmen Cabanelas Pazos-Moura
Journal:  Ther Adv Endocrinol Metab       Date:  2020-05-13       Impact factor: 3.565

5.  Circulating Irisin Level and Thyroid Dysfunction: A Systematic Review and Meta-Analysis.

Authors:  Dan Shan; Li Zou; Xijiao Liu; Yitong Cai; Ruihong Dong; Yayi Hu
Journal:  Biomed Res Int       Date:  2020-10-28       Impact factor: 3.411

Review 6.  The Potential Role of Irisin in Vascular Function and Atherosclerosis: A Review.

Authors:  Kyeongho Byun; Sewon Lee
Journal:  Int J Mol Sci       Date:  2020-09-29       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.